# A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells

> **NCT01711346** · PHASE2 · COMPLETED · sponsor: **Cerus Corporation** · enrollment: 42 (actual)

## Conditions studied

- Focus: Assess Post Infusion Viability of S303 RBCs

## Interventions

- **BIOLOGICAL:** S303 Red Blood Cells (RBCs)
- **BIOLOGICAL:** Conventional, untreated Red Blood Cells (RBCs)

## Key facts

- **NCT ID:** NCT01711346
- **Lead sponsor:** Cerus Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-07
- **Final completion:** 2014-11
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2015-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01711346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01711346, "A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01711346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*